Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ESPR

ESPR - Esperion Therapeutics Inc Stock Price, Fair Value and News

2.91USD+0.02 (+0.69%)Market Closed

Market Summary

ESPR
USD2.91+0.02
Market Closed
0.69%

ESPR Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

ESPR Stock Price

View Fullscreen

ESPR RSI Chart

ESPR Valuation

Market Cap

551.3M

Price/Earnings (Trailing)

-6.37

Price/Sales (Trailing)

2.4

Price/Free Cashflow

-16.45

ESPR Price/Sales (Trailing)

ESPR Profitability

Return on Equity

29.39%

Return on Assets

-23.19%

Free Cashflow Yield

-6.08%

ESPR Fundamentals

ESPR Revenue

Revenue (TTM)

229.7M

Rev. Growth (Yr)

466.14%

Rev. Growth (Qtr)

327.09%

ESPR Earnings

Earnings (TTM)

-86.5M

Earnings Growth (Yr)

198.87%

Earnings Growth (Qtr)

208.3%

Breaking Down ESPR Revenue

Last 7 days

17.8%

Last 30 days

33.5%

Last 90 days

40.6%

Trailing 12 Months

136.6%

How does ESPR drawdown profile look like?

ESPR Financial Health

Current Ratio

2.22

Debt/Equity

5e-4

Debt/Cashflow

-195.02

ESPR Investor Care

Shares Dilution (1Y)

100.04%

Diluted EPS (TTM)

-0.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024229.7M000
202381.0M87.9M102.9M116.3M
202289.3M67.5M72.1M75.5M
2021233.7M62.1M72.7M78.4M
2020168.2M188.0M207.8M227.5M
2019000148.4M

Tracking the Latest Insider Buys and Sells of Esperion Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 23, 2024
shepard jay
acquired
-
-
23,000
-
May 23, 2024
fischer seth h. z.
acquired
-
-
23,000
-
May 23, 2024
fuhrman alan
acquired
-
-
23,000
-
May 23, 2024
carroll j martin
acquired
-
-
23,000
-
May 23, 2024
rocamboli stephen
acquired
-
-
23,000
-
May 23, 2024
gotto antonio m jr md d phil
acquired
-
-
23,000
-
May 17, 2024
warren eric
sold
-953
2.483
-384
chief commercial officer
Mar 14, 2024
halladay benjamin
acquired
-
-
170,000
chief financial officer
Mar 14, 2024
warren eric
acquired
-
-
100,000
chief commercial officer

1–10 of 50

Which funds bought or sold ESPR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
Cetera Investment Advisers
new
-
41,594
41,594
-%
May 17, 2024
Ikarian Capital, LLC
sold off
-100
-1,009,530
-
-%
May 16, 2024
COMERICA BANK
new
-
40.00
40.00
-%
May 16, 2024
JANE STREET GROUP, LLC
added
256
1,811,170
2,635,360
-%
May 15, 2024
ARISTEIA CAPITAL, L.L.C.
unchanged
-
-21,997
190,170
-%
May 15, 2024
BOOTHBAY FUND MANAGEMENT, LLC
reduced
-51.03
-162,278
126,954
-%
May 15, 2024
ORBIMED ADVISORS LLC
new
-
36,739,400
36,739,400
0.67%
May 15, 2024
ARMISTICE CAPITAL, LLC
sold off
-100
-9,568,000
-
-%
May 15, 2024
LMR Partners LLP
new
-
62,524
62,524
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
235
57,519
86,223
-%

1–10 of 37

Are Funds Buying or Selling ESPR?

Are funds buying ESPR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ESPR
No. of Funds

Unveiling Esperion Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 12, 2024
millennium management llc
5.4%
10,176,529
SC 13G
Feb 14, 2024
two seas capital lp
6.8%
7,686,120
SC 13G/A
Feb 14, 2024
deep track capital, lp
0%
0
SC 13G/A
Feb 14, 2024
cvi investments, inc.
0%
0
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
0.1%
4,800
SC 13G/A
Feb 13, 2024
vanguard group inc
4.52%
5,137,750
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Jan 24, 2024
bb biotech ag
5.1%
9,194,064
SC 13G/A
Jan 24, 2024
bb biotech ag
3.7%
4,194,064
SC 13G/A
Jan 17, 2024
millennium management llc
3.2%
3,643,951
SC 13G/A

Recent SEC filings of Esperion Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
SC 13G
Major Ownership Report
May 28, 2024
8-K
Current Report
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading

Peers (Alternatives to Esperion Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.94% -10.00%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.54% 19.05%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-4.21% 34.20%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.61% -29.78%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-6.10% -18.51%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
1.81% 133.24%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.31% -21.88%
9.66
2.43
54.01% 364.56%
3.7B
4.6B
-9.61% -18.87%
-484.73
0.82
-0.06% 94.55%
2.3B
9.0B
-13.20% -15.57%
-4.98
0.25
10.01% -27.45%
2.0B
676.2M
-1.62% -15.25%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-16.75% 6.10%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-2.94% -47.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-19.67% -19.01%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.66%
-0.32
0.11
66.16% 61.84%
347.8K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Esperion Therapeutics Inc News

Latest updates
MarketBeat10 hours ago
InvestorPlace07 May 202407:00 am

Esperion Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue327.1%13832.0034.0026.0024.0019.0019.0019.0019.0015.0014.0041.008.0010.004.002121071.001.001.00145
Operating Expenses-12.3%65.0075.0062.0063.0073.0061.0061.0071.0062.0071.0070.0073.0091.0010584.0083.0076.0060.0067.0056.0058.00
  S&GA Expenses-7.6%42.0045.0033.0034.0030.0024.0025.0030.0030.0038.0039.0046.0061.0062.0049.0048.0042.0022.0018.0013.0012.00
Interest Expenses-6.9%14.0015.0015.0015.0014.0014.0014.0014.0014.0013.0014.0011.008.009.005.005.004.004.004.00--
Net Income208.3%61.00-56.34-41.25-49.93-61.72-55.49-55.12-66.32-56.73-65.12-69.39-43.67-90.93-104-85.44125-78.25-61.95-68.38-54.2287.00
Net Income Margin79.1%-0.38*-1.80*-2.03*-2.53*-2.95*-3.10*-3.38*-3.82*-2.63*-3.43*-4.24*-5.23*---------
Free Cashflow-54.00--19.32-24.75-54.36-42.47-42.83-50.53-38.99-57.71-69.17-47.87-89.07--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets81.3%373206221235252248313304343382225280279353251330180214255309236
  Current Assets81.8%366201218232251247262252291329171275273346243321173212253307235
    Cash Equivalents175.5%22782.00115138145125159123150259104219218305216298149167212274175
  Inventory11.4%73.0066.0051.0046.0039.0035.0030.0029.0036.0034.0034.0024.0020.0016.009.008.002.00----
  Net PPE-0.00-0.000.000.000.000.000.001.001.001.001.001.001.001.002.001.001.001.001.000.00
Liabilities1.0%66766163160758157260759659257958858554844924224523019418717961.00
  Current Liabilities5.3%16515613810795.0092.0082.0082.0079.0073.0078.0083.0098.0094.0076.0084.0073.0066.0058.0054.0060.00
Shareholder's Equity35.3%-294-454---329-323--------9.0085.00-20.0069.00129175
  Retained Earnings3.9%-1,488-1,549-1,492-1,451-1,401-1,340-1,284-1,229-1,163-1,106-1,041-971-928-838-734-648-773-695-633-564-510
  Additional Paid-In Capital8.7%1,2491,1491,1381,1351,1271,0711,045993969964734723714798743734723715702694686
Shares Outstanding64.2%16910310010978.0066.0064.0062.0061.0029.0026.0026.00---------
Float----143---422---593---1,410---1,090-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations245.3%53,828-37,056-19,325-24,750-54,356-42,472-42,833-50,532-38,990-57,706-69,169-47,866-89,068-68,550-86,671139,391-69,347-49,994-58,029-54,00991,691
  Share Based Compensation10.8%3,2352,9202,9753,1602,9033,7153,5373,5274,4364,4745,4978,5845,7516,6737,2647,3957,0536,3586,3276,5636,636
Cashflow From Investing-Infinity%-73.00--17,50025,000-11,79433,0005,000-18,102-50,484----12,6762,3335,11026,589-2,868-5,31326,71645,696
Cashflow From Financing1926.5%90,6064,471-4,31280949,492-30,35846,29218,108-1,436213,4103,65549,1132,045170,4401,5973,67426,0147,014976126,5361,669
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ESPR Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total Revenues$ 137,735$ 24,329
Operating expenses:  
Cost of goods sold10,07511,652
Research and development13,40331,381
Selling, general and administrative41,98829,901
Total operating expenses65,46672,934
Income (loss) from operations72,269(48,605)
Interest expense(14,024)(14,387)
Other income, net2,7771,273
Net income (loss)$ 61,022$ (61,719)
Net income (loss) per common share - basic (in dollars per share)$ 0.36$ (0.79)
Net income (loss) per common share - diluted (in dollars per share)$ 0.34$ (0.79)
Weighted-average shares outstanding - basic (in shares)169,258,56478,440,266
Weighted-average shares outstanding - diluted (in shares)189,641,25178,440,266
Other comprehensive income (loss):  
Unrealized gain on investments$ 0$ 1
Comprehensive income (loss)61,022(61,718)
Product sales, net  
Revenues:  
Total Revenues24,75617,031
Collaboration revenue  
Revenues:  
Total Revenues$ 112,979$ 7,298

ESPR Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 226,609$ 82,248
Accounts receivable54,61248,494
Prepaid clinical development costs0193
Inventories, net73,09565,623
Other prepaid and current assets11,2904,507
Total current assets365,606201,065
Noncurrent assets:  
Property and equipment, net2680
Right of use operating lease assets7,1304,675
Intangible assets5656
Total assets373,060205,796
Current liabilities:  
Accounts payable28,43331,718
Accrued clinical development costs3,0463,441
Accrued variable consideration34,51834,284
Other accrued liabilities23,14024,998
Revenue interest liability43,48634,828
Deferred revenue from collaborations29,35025,402
Operating lease liabilities2,5391,553
Total current liabilities164,512156,224
Noncurrent liabilities:  
Convertible notes, net of issuance costs262,033261,596
Revenue interest liability236,397239,950
Operating lease liabilities4,4163,020
Total liabilities667,358660,790
Commitments and contingencies (Note 5)
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; 480,000,000 shares authorized as of March 31, 2024 and 480,000,000 shares authorized as of December 31, 2023; 189,849,296 shares issued at March 31, 2024 and 120,204,513 shares issued at December 31, 2023188118
Additional paid-in capital1,248,7741,149,170
Treasury stock, at cost; 1,994,198 shares at March 31, 2024 and December 31, 2023(54,998)(54,998)
Accumulated other comprehensive income (loss)00
Accumulated deficit(1,488,262)(1,549,284)
Total stockholders’ deficit(294,298)(454,994)
Total liabilities and stockholders’ deficit$ 373,060$ 205,796
ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
 CEO
 WEBSITEesperion.com
 INDUSTRYPharmaceuticals
 EMPLOYEES199

Esperion Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Esperion Therapeutics Inc? What does ESPR stand for in stocks?

ESPR is the stock ticker symbol of Esperion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Esperion Therapeutics Inc (ESPR)?

As of Thu Jun 13 2024, market cap of Esperion Therapeutics Inc is 551.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ESPR stock?

You can check ESPR's fair value in chart for subscribers.

What is the fair value of ESPR stock?

You can check ESPR's fair value in chart for subscribers. The fair value of Esperion Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Esperion Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ESPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Esperion Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ESPR is over valued or under valued. Whether Esperion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Esperion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ESPR.

What is Esperion Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, ESPR's PE ratio (Price to Earnings) is -6.37 and Price to Sales (PS) ratio is 2.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ESPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Esperion Therapeutics Inc's stock?

In the past 10 years, Esperion Therapeutics Inc has provided -0.149 (multiply by 100 for percentage) rate of return.